‡: Medical Insight, Inc 2022. Cosmetic Neurotoxin Market Study. January 2022. Based on worldwide neurotoxins 2021 (in sales value). #: BOTOX^® Prescribing Information. HK-41906. May 2013. Ɨ: Allergan Aesthetics. Data on File. REF-119535. Total number of BOTOX vials shipped as of 5 December 2022.
^: U.S. Food and Drug Administration, Department of Health & Human Services. Botox approval letter SUPPL-5303, October 2, 2017.
References: 1. Trindade de Almeida A et al. Dermatol Surg 2015; 41: S19-S28. 2. Yu W et al. J Cosmet Laser Ther. 2018Oct;20(5):278-286. 3. U.S. Food and Drug Administration, Department of Health & Human Services. Botox approval letter 85-0226 & 85-0227, December 29, 1989. 4. Allergan. Unpublished Data. INT-BCT-2050129 – Worldwide BOTOX^® marketing authorization status. October 2020. 5. Allergan. Unpublished Data. REF-100250. BOTOX^® number of peer-reviewed articles vs competitors. August 2022. 6. Michaud T, et al. J Cosmet Dermatol. 2015;14(1):9–21. 7. DasGupta BR. Structures of botulinum neurotoxin, its functional domains, and perspectives on the crystalline type A toxin. In: Jankovic J, Hallet, M., ed. Therapy with Botulinum Toxin. New York, NY: Marcel Decker, Inc; 1994: 15-39. 8. Coffield JA, Considine RV, Simpson LL. The site and mechanism of action of botulinum neurotoxin. In: Jankovic J, Hallet, M., ed. Therapy with Botulinum Toxin. New York, NY: Marcel Dekker, Inc; 1994:3-13. 9. Schantz EJ, Johnson EA. Preparation and characterization of botulinum toxin type A for human treatment. In: Jankovic J, Hallet, M., ed. Therapy with Botulinum Toxin. New York, NY: Marcel Dekker, Inc; 1994:41-49. 10. Simpson LL. The actions of clostridial toxins on storage and release of neurotransmitters. In: Harvey AL, ed. Natural and Synthetic Neurotoxins (Neuroscience Perspectives). San Diego, CA: Academic Press; 1993:278-317. 11. Black JD, Dolly JO. Interaction of 125I-labeled botulinum neurotoxins with nerve terminals II. Autoradiographic evidence for its uptake into motor nerves by acceptor-mediated endocytosis. J Cell Biol. 1986;103(2):535-544. 12. Lebeda FJ, Hack DC, Bentry MK. Theoretical analyses of the functional regions of the heavy chain of botulinum neurotoxin. In: Jankovic J, Hallet M, ed. Therapy with Botulinum Toxin. New York, NY: Marcel Dekker, Inc; 1994:51-61. 13. Harvey AL. Presynaptic toxins. In: Smythies JR, Bradley RJ, ed. International Review of. 14. Neurobiology. San Diego, CA: Academic Press; 1990:201-239. 15. Tremaine AM, McCullough JL. Clin Cosmet Investig Dermatol. 2010;3:15–23. 16. Stotland MA et al. Plast Reconstr Surg 2007; 120(5):1386-9. 17. Beer KR et al. J Drugs Dermatol 2011;10:39-41. 18. De Boulle K et al. Dermatol Surg. 2018;44[11]:1437-1448. 19. De Maio M, et al. Plast Reconstr Surg. 2017 Aug;140(2):265e-276e. 20. Juvéderm^® (Hyaluronic Acid Gel with Lidocaine) product series includes VOLUX™ (HKMD-190341), VOLUMA^® (HKMD-100411), VOLIFT^® (HKMD-130324), VOLBELLA^® (HKMD-210451) and VOLITE™ (HKMD-180040).

BOTOX^®保妥適^®(Botulinum Toxin Type A)藥品註冊編號: HK-41906. BOTOX^®為醫生處方藥物，請向醫生或醫學美容中心
諮詢切合您獨特需要的專屬療程方案。療程效果因人而異。療程後如有任何不良反應，請即向醫生查詢
© 2024 Allergan Aesthetics. All rights reserved. All adverse events should be reported to drugsafety.pv@abbvie.com.


HK-BCT-240047 | 30/SEP/24
香港北角電氣道 183 號友邦廣場 24 樓 2404-08 室        電話: (852)26102525